The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Yun Fan,Yang Shao,Yanjun Xu,Xiaoling Tong,Junrong Yan,Xue Wu

doi:10.1200/jco.2018.36.15_suppl.e21237

The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Yun Fan, Yang Shao + Show 4 more

https://doi.org/10.1200/jco.2018.36.15_suppl.e21237

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2018

Affiliation: Zhejiang Cancer Hospital, Nanjing Medical University

#EGFR Mutations In Exon #Non-small Cell Lung Cancer #Primary Resistance Mechanisms #Activating EGFR Mutations #Mutations In Exon #Tyrosine Kinase Inhibitors #Mutation Mechanisms #Primary Mechanisms #EGFR Tyrosine Kinase Inhibitors #Short-term Responders

Abstract
Full-Text
Similar Papers

Abstract

Listen

e21237Background: Non-small cell lung cancer (NSCLC) with activating EGFR mutations in exon 19 or 21 usually responds to EGFR tyrosine kinase inhibitors (TKIs), but sometimes the responses can only...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.